DiaSorin S.p.A
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under L… Read more
DiaSorin S.p.A (DSRLF) - Total Assets
Latest total assets as of June 2025: $2.87 Billion USD
Based on the latest financial reports, DiaSorin S.p.A (DSRLF) holds total assets worth $2.87 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DiaSorin S.p.A - Total Assets Trend (2003–2024)
This chart illustrates how DiaSorin S.p.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DiaSorin S.p.A - Asset Composition Analysis
Current Asset Composition (December 2024)
DiaSorin S.p.A's total assets of $2.87 Billion consist of 28.2% current assets and 71.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.4% |
| Accounts Receivable | $194.70 Million | 5.9% |
| Inventory | $344.04 Million | 10.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.18 Billion | 35.8% |
| Goodwill | $846.86 Million | 25.6% |
Asset Composition Trend (2003–2024)
This chart illustrates how DiaSorin S.p.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DiaSorin S.p.A's current assets represent 28.2% of total assets in 2024, a decrease from 44.8% in 2003.
- Cash Position: Cash and equivalents constituted 10.4% of total assets in 2024, up from 3.2% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, an increase from 34.0% in 2003.
- Asset Diversification: The largest asset category is intangible assets at 35.8% of total assets.
DiaSorin S.p.A Competitors by Total Assets
Key competitors of DiaSorin S.p.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
DiaSorin S.p.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - DiaSorin S.p.A generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, DiaSorin S.p.A generates $5.69 in net profit.
DiaSorin S.p.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 3.12 | 3.91 |
| Quick Ratio | 0.78 | 1.89 | 2.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $204.18 Million | $ 564.50 Million | $ 443.40 Million |
DiaSorin S.p.A - Advanced Valuation Insights
This section examines the relationship between DiaSorin S.p.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.35 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | 2.9% |
| Total Assets | $3.30 Billion |
| Market Capitalization | $2.65 Billion USD |
Valuation Analysis
Below Book Valuation: The market values DiaSorin S.p.A's assets below their book value (0.80 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: DiaSorin S.p.A's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for DiaSorin S.p.A (2003–2024)
The table below shows the annual total assets of DiaSorin S.p.A from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.30 Billion | +2.91% |
| 2023-12-31 | $3.21 Billion | -5.77% |
| 2022-12-31 | $3.41 Billion | +5.48% |
| 2021-12-31 | $3.23 Billion | +159.23% |
| 2020-12-31 | $1.25 Billion | +17.20% |
| 2019-12-31 | $1.06 Billion | +17.40% |
| 2018-12-31 | $905.94 Million | -4.21% |
| 2017-12-31 | $945.72 Million | +8.88% |
| 2016-12-31 | $868.62 Million | +22.70% |
| 2015-12-31 | $707.91 Million | +16.88% |
| 2014-12-31 | $605.69 Million | +15.02% |
| 2013-12-31 | $526.62 Million | +0.30% |
| 2012-12-31 | $525.02 Million | +10.72% |
| 2011-12-31 | $474.20 Million | +5.94% |
| 2010-12-31 | $447.63 Million | +32.86% |
| 2009-12-31 | $336.91 Million | +27.27% |
| 2008-12-31 | $264.72 Million | +27.07% |
| 2007-12-31 | $208.33 Million | +7.34% |
| 2006-12-31 | $194.08 Million | +8.25% |
| 2005-12-31 | $179.28 Million | -0.49% |
| 2004-12-31 | $180.16 Million | -3.76% |
| 2003-12-31 | $187.21 Million | -- |